| Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study.Arthritis Rheumatol | PMID 38556921无 PMCID | 2024-Aug | 0.95 | The study is a randomized Phase IIIb trial of drug interventions (secukinumab vs. adalimumab biosimilar) with original results, but the condition is axial spondyloarthritis, a non-oncologic inflammatory disease. The primary endpoint is radiographic progression (mSASSS), a structural outcome, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) typical for oncology Kaplan-Meier digitization. | 待处理 |
| Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.J Am Acad Dermatol | PMID 38588819无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cariprazine as a maintenance therapy in the prevention of mood episodes in adults with bipolar I disorder.Bipolar Disord | PMID 38609342无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mitral Regurgitation in Obstructive Hypertrophic Cardiomyopathy: Insight from the VALOR-HCM Study.JACC Cardiovasc Imaging | PMID 38639695无 PMCID | 2024-Aug | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up.J Thorac Oncol | PMID 38642841无 PMCID | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).Br J Haematol | PMID 38654616无 PMCID | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC).Bone Marrow Transplant | PMID 38664589PMC11296945 | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and Efficacy of 2.5 mg and 1.25 mg Nebulized Salbutamol Compared with Placebo on Transient Tachypnea of the Newborns: A Triple-Blind Phase II/III Parallel Randomized Controlled Trial.J Aerosol Med Pulm Drug Deliv | PMID 38687321无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial.Eur Urol | PMID 38692956无 PMCID | 2024-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial.Eur J Haematol | PMID 38693052无 PMCID | 2024-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial.Lancet Respir Med | PMID 38701817PMC11296889 | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial.J Urol | PMID 38708869PMC12721610 | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Optimization of cerebral oxygenation based on regional cerebral oxygen saturation monitoring during carotid endarterectomy: a Phase III multicenter, double-blind randomized controlled trial.Anaesth Crit Care Pain Med | PMID 38710323无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).Diabetes Obes Metab | PMID 38715179无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pharmacokinetics/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial.Br J Clin Pharmacol | PMID 38715387无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 Study.Mov Disord | PMID 38725190无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.Ann Oncol | PMID 38729566无 PMCID | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause.Maturitas | PMID 38749864无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Inclisiran in individuals with diabetes or obesity: Post hoc pooled analyses of the ORION-9, ORION-10 and ORION-11 Phase 3 randomized trials.Diabetes Obes Metab | PMID 38757725无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Early versus late follicular phase ovarian stimulation: a randomized controlled trial.Reprod Biomed Online | PMID 38763121无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mirikizumab Exposure-Response Relationships in Patients with Moderately-to-Severely Active Ulcerative Colitis in Randomized Phase II and III Studies.Clin Pharmacol Ther | PMID 38797892无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Stereotactic radiotherapy vs whole brain radiation therapy in EGFR mutated NSCLC: Results & reflections from the prematurely closed phase III HYBRID trial.Radiother Oncol | PMID 38801945无 PMCID | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221.Cancer Chemother Pharmacol | PMID 38814343PMC11878155 | 2024-Aug | 0.80 | This is a secondary analysis of a Phase III randomized trial (SWOG S0221) in human oncology, but it reports on a toxicity endpoint (chemotherapy-induced peripheral neuropathy) rather than survival, progression, recurrence, death, or time-to-event efficacy outcomes. | 待处理 |
| Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.Lancet Gastroenterol Hepatol | PMID 38823398无 PMCID | 2024-Aug | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.Nat Med | PMID 38824242无 PMCID | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial.Nat Med | PMID 38824243无 PMCID | 2024-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.Nat Med | PMID 38825627PMC11333275 | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.Nat Med | PMID 38830994PMC11333283 | 2024-Aug | 0.85 | The trial meets oncology, human, randomized, phase 3, drug intervention, and original result criteria. However, the primary endpoint is MRD negativity (a biomarker), and the survival data are immature and lack Kaplan-Meier curves or hazard ratios, thus failing to meet the time-to-event efficacy endpoint requirement for inclusion. | 待处理 |
| Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.Gynecol Oncol | PMID 38833992PMC12124154 | 2024-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.Clin Rheumatol | PMID 38844682PMC11269379 | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.Nat Med | PMID 38844797PMC11333288 | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients.Int J Antimicrob Agents | PMID 38851462无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.Ann Oncol | PMID 38866180无 PMCID | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).Br J Cancer | PMID 38866963PMC11300911 | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.Br J Haematol | PMID 38867615无 PMCID | 2024-Aug | 0.80 | The record describes a Phase III randomized trial in follicular lymphoma, but the reported analysis is on vaccine immunogenicity, not a primary or key secondary time-to-event efficacy endpoint like OS or PFS. It is a secondary analysis within a larger trial, not the primary efficacy report. | 待处理 |
| Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: NEDA-3 After Re-Baselining in the Phase 3 EVOLVE-MS-1 Study.Adv Ther | PMID 38878121PMC11263382 | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.Lancet Microbe | PMID 38878794无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer.Breast | PMID 38880077PMC11228587 | 2024-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4·5 h of onset of ischaemic stroke (TASTE): a multicentre, randomised, controlled, phase 3 non-inferiority trial.Lancet Neurol | PMID 38880118无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study.Lancet Haematol | PMID 38885672无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.Lancet Oncol | PMID 38889735PMC12375812 | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| No add-on therapeutic benefit of at-home anodal tDCS of the primary motor cortex to mindfulness meditation in patients with fibromyalgia.Clin Neurophysiol | PMID 38901112无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of E4/DRSP on self-reported physical and emotional premenstrual and menstrual symptoms: data from the phase 3 clinical trial in Europe and Russia.Eur J Contracept Reprod Health Care | PMID 38904165无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.Lancet Gastroenterol Hepatol | PMID 38906161无 PMCID | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation.Eur J Cancer | PMID 38924855无 PMCID | 2024-Aug | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF.Eur J Heart Fail | PMID 38932589无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.Lancet Oncol | PMID 38942046PMC11323681 | 2024-Aug | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial.CNS Drugs | PMID 38954317PMC11258069 | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.Eur Neuropsychopharmacol | PMID 38954874无 PMCID | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Dose-exposure-efficacy response of intravenous immunoglobulin G 10% in multifocal motor neuropathy.Ann Clin Transl Neurol | PMID 38978354PMC11330225 | 2024-Aug | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |